<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04977986</url>
  </required_header>
  <id_info>
    <org_study_id>ZYN2-CL-033</org_study_id>
    <nct_id>NCT04977986</nct_id>
  </id_info>
  <brief_title>Clinical Study of Cannabidiol in Children and Adolescents With Fragile X Syndrome</brief_title>
  <acronym>RECONNECT</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome - RECONNECT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zynerba Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zynerba Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the&#xD;
      efficacy and safety of Cannabidiol (CBD) administered as ZYN002 for the treatment of children&#xD;
      and adolescent patients with Fragile X Syndrome (FXS). Eligible participants will participate&#xD;
      in up to an 18 week treatment period, where all participants will receive placebo or active&#xD;
      study drug. Patients ages 3 to &lt; 18 years, will be eligible to participate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the&#xD;
      efficacy and safety of ZYN002, a pharmaceutically manufactured CBD, formulated as a clear gel&#xD;
      that can be applied to the skin (called transdermal delivery), in children and adolescents&#xD;
      with FXS. 204 male and female patients, ages 3 to &lt; 18 years, will be randomized 1:1 to&#xD;
      either trial drug or placebo and will undergo a 18-week treatment period. Randomization will&#xD;
      be stratified by gender, methylation status and weight. The study will be comprised of a&#xD;
      Screening visit and a combination of seven visits both onsite (face-to-face) and virtual. The&#xD;
      assignment of study drug or placebo will be done by a computer generated system and neither&#xD;
      the study doctor, participant or their caregivers will know which treatment is being given to&#xD;
      them. The dose of the treatment will depend on the weight of the participants. If the&#xD;
      participants weigh less than or equal to 30 kg, they will receive 2 sachets of the gel per&#xD;
      day (1 sachet approximately every 12 hours). If the participant weighs more than 30 kg but&#xD;
      less than or equal to 50 kg, they will receive 4 sachets of gel per day (2 sachets&#xD;
      approximately every 12 hours). Participants who weigh more than 50 kg will receive 6 sachets&#xD;
      of gel per day (3 sachets approximately every 12 hours). Parents/ caregivers will be&#xD;
      instructed on proper application of the gel. The gel will be applied to clean, dry, intact&#xD;
      skin of the upper arms/ shoulders.&#xD;
&#xD;
      Blood samples will be collected for safety analysis of ZYN002. An independent analytical&#xD;
      laboratory will also perform CGG repeat and methylation status analyses. Additionally, the&#xD;
      parents/caregivers and study doctor will be asked to complete some questionnaires for&#xD;
      efficacy and safety assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-Blind, Placebo-controlled, multiple center study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo formulated as a clear gel (transdermal delivery)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Aberrant Behavior Checklist-Community Fragile X Factor Structure (ABC-C FXS) Pre-specified Subscale 1 score in patients with complete methylation (100%) of the FMR1 gene.</measure>
    <time_frame>Change from Baseline to Week 18</time_frame>
    <description>The ABC-C FXS is a standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aberrant Behavior Checklist-Community, Fragile X Factor Structure (ABC-C FXS) Pre-specified Subscale 2 in patients with complete methylation (100%) of the FMR1 gene.</measure>
    <time_frame>Change from Baseline to Week 18</time_frame>
    <description>The ABC-C FXS is a standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on the Caregiver Global Impression of Change (CaGI-C) for Pre-specified parameter among patients with complete methylation (100%) of the FMR1 gene.</measure>
    <time_frame>Change from Baseline to Week 18</time_frame>
    <description>The CaGI-C global impression of change is a 7-point Likert scale designed to measure behavioral symptomatic change at a specific time compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression- Improvement (CGI-I) scale among patients with complete methylation (100%) of the FMR1 gene.</measure>
    <time_frame>Change from Baseline to Week 18</time_frame>
    <description>The CGI-I global improvement item is a 7-point Likert scale to rate the behavioral change in a child at a specified time compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ABC-C FXS pre-specified Subscale 1 among all randomized patients (complete and partial methylation of the FMR1 gene).</measure>
    <time_frame>Change from Baseline to Week 18</time_frame>
    <description>The ABC-C FXS is a standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Day 1, Week 2, Week 4, Week 6, Week 10, Week 14, Week 18 and through 4-week post-dose telephone follow-up</time_frame>
    <description>Collection of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal physical and neurological exams</measure>
    <time_frame>Screening, Day 1 and Week 18</time_frame>
    <description>Physical and neurological exams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal clinical laboratory results</measure>
    <time_frame>Screening, Week 10 and Week 18</time_frame>
    <description>Laboratory tests and urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal vital sign results</measure>
    <time_frame>Screening, Day 1, Week 2 and Week 18</time_frame>
    <description>Vital sign measurements (blood pressure, heart rate, respiratory rate and temperature)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal ECG</measure>
    <time_frame>Screening and Week 18</time_frame>
    <description>12-lead ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawal characteristics of ZYN002 using the Penn Physician Withdrawal Checklist</measure>
    <time_frame>Week 18 and 4-week post last dose</time_frame>
    <description>Penn Physician Withdrawal Checklist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin tolerability as assessed using daily skin diary</measure>
    <time_frame>Daily from Day 1 through Week 18</time_frame>
    <description>Daily skin irritation diary</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Fragile X Syndrome</condition>
  <arm_group>
    <arm_group_label>ZYN002 - CBD transdermal gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmaceutically manufactured. Cannabidiol (CBD) is formulated as a clear gel for transdermal delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo transdermal gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is formulated as a clear gel for transdermal delivery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZYN002 - CBD transdermal gel</intervention_name>
    <description>Pharmaceutically manufactured cannabidiol (CBD) formulated as a clear gel that can be applied to the skin (transdermal delivery)</description>
    <arm_group_label>ZYN002 - CBD transdermal gel</arm_group_label>
    <other_name>CBD formulated as a clear gel that can be applied to the skin (transdermal delivery)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo formulated as a clear gel that can be applied to the skin (transdermal delivery)&#xD;
Other Names:&#xD;
Placebo Comparator Matching Placebo</description>
    <arm_group_label>Placebo transdermal gel</arm_group_label>
    <other_name>Placebo Comparator</other_name>
    <other_name>Matching Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female children and adolescents aged 3 to &lt; 18 years, at the time of&#xD;
             Screening.&#xD;
&#xD;
          -  Judged by the Investigator to be in generally good health at Screening based upon the&#xD;
             results of medical history, physical exam, 12-lead ECG and clinical laboratory test&#xD;
             results. -Laboratory results outside the reference range must be documented as not&#xD;
             clinically significant by both the Investigator and Sponsor.&#xD;
&#xD;
          -  Participants must have a diagnosis of FXS through molecular documentation of full&#xD;
             mutation of the FMR1 gene documented through genetic testing at Screening.&#xD;
&#xD;
          -  Patients with a history of seizure disorders must currently be receiving treatment&#xD;
             with a stable regimen of no more than two anti-seizure medications (ASMs) for the four&#xD;
             weeks preceding study Screening; or must be seizure-free for one year if not currently&#xD;
             receiving ASMs.&#xD;
&#xD;
          -  Patients taking psychoactive medication(s) should be on a stable regimen of not more&#xD;
             than three such medications for at least fours weeks preceding Screening and must&#xD;
             maintain that regimen throughout the study. Psychoactive medications include (but are&#xD;
             not limited to) antipsychotics, antidepressants, anxiolytics, attention-deficit /&#xD;
             hyperactivity disorder (ADHD) medications, and medications for sleep.&#xD;
&#xD;
          -  If patients are receiving non-pharmacological, behavioral and/or dietary&#xD;
             interventions, they must be stable and have been doing so for three months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Patients have a body mass index between 12-30 kg/m2 (inclusive).&#xD;
&#xD;
          -  Females of childbearing potential must have a negative serum pregnancy test at the&#xD;
             Screening Visit and a negative serum or urine pregnancy test at all designated visits.&#xD;
&#xD;
          -  Patients and parents/caregivers must be adequately informed of the nature and risks of&#xD;
             the study and given written informed consent prior to Screening.&#xD;
&#xD;
          -  Patients and parents/caregivers agree to abide by all study restrictions and comply&#xD;
             with all study procedures, and in the Investigator's opinion, are reliable and willing&#xD;
             and able to comply with all protocol requirements and procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant, nursing or planning a pregnancy; females of childbearing&#xD;
             potential and male patients with a partner of childbearing potential who are unwilling&#xD;
             or unable to use an acceptable method of contraception as outlined below for the&#xD;
             duration of therapy and for three months after the last dose of study medication.&#xD;
             Standard acceptable methods of contraception include abstinence or the use of a highly&#xD;
             effective method of contraception, including hormonal contraception, diaphragm,&#xD;
             cervical cap, vaginal sponge, condom, spermicide, vasectomy, or intrauterine device.&#xD;
&#xD;
          -  History of significant allergic condition, significant drug-related hypersensitivity,&#xD;
             or allergic reaction to any compound or chemical class related to ZYN002 or its&#xD;
             excipients.&#xD;
&#xD;
          -  Exposure to any investigational drug or device less than or equal to 30 days prior to&#xD;
             Screening or at any time during the study.&#xD;
&#xD;
          -  Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or total bilirubin&#xD;
             levels greater than or equal to 2 times the upper limit of normal or alkaline&#xD;
             phosphatase levels greater than or equal to 3 times the upper limit of normal.&#xD;
&#xD;
          -  Use of cannabis or any THC or CBD-containing product within 3 months of Screening&#xD;
             Visit or during the study (aside from ZYN002).&#xD;
&#xD;
          -  Patient has a positive drug screen, including ethanol, cocaine, THC, barbiturates,&#xD;
             amphetamines (unless prescribed), benzodiazepines (except midazolam or comparable&#xD;
             administered for blood draws and ECG collection), and opiates.&#xD;
&#xD;
          -  Patient is using the following AEDs (medications for the treatment of seizures and/ or&#xD;
             epilepsy): clobazam, phenobarbital, ethosuximide, felbamate, carbamazepine, phenytoin,&#xD;
             or vigabatrin.&#xD;
&#xD;
          -  Patient is using a strong inhibitor/inducer of CYP3A4 or sensitive substrate of CYP3A4&#xD;
             including but not limited to the following medications: midazolam (except single doses&#xD;
             administered for the purposes of obtaining blood samples and ECG's), oral&#xD;
             ketoconazole, fluconazole, nefazadone, rifampin, alfentanil, alfuzosin, amiodarone,&#xD;
             cyclosporine, dasatinib, docetaxol, eplerenone, ergotamine, everolimus, fentanyl,&#xD;
             halofantrine, irinotecan, lapatinib, levomethadyl, lumefantrine, nilotinib, pimozide,&#xD;
             quinidine, ranolazine, sirolimus, tacrolimus, temsirolimus, toremifene, tretinioin,&#xD;
             vincristine, vinorelbine, St. John's Wort, and grapefruit Juice/products.&#xD;
&#xD;
          -  Patients may not be taking any benzodiazepines (except single doses administered for&#xD;
             the purposes of obtaining blood samples and ECGs) at screening or throughout the&#xD;
             study.&#xD;
&#xD;
          -  Patient is expected to initiate or change pharmacologic or non-pharmacologic&#xD;
             interventions during the course of the study.&#xD;
&#xD;
          -  Patient has an advanced, severe, or unstable disease that may interfere with the study&#xD;
             outcome evaluations.&#xD;
&#xD;
          -  Patient has acute or progressive neurological disease, psychosis, schizophrenia or any&#xD;
             other psychiatric disorder or severe mental abnormalities (other than FXS) that are&#xD;
             likely to require changes in drug therapy or interfere with the study objectives or&#xD;
             ability to adhere to protocol requirements.&#xD;
&#xD;
          -  Patient has a positive result for the presence of HBsAg, HCV, or HIV antibodies.&#xD;
&#xD;
          -  Patient has known history of cardiovascular disease, advanced arteriosclerosis,&#xD;
             structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities,&#xD;
             coronary artery disease, cardiac conduction problems, exercise-related cardiac events&#xD;
             including syncope and pre-syncope, risk factors for Torsades de pointes (TdP) (e.g.,&#xD;
             heart failure, hypokalemia, family history of Long QT Syndrome), or other serious&#xD;
             cardiac problems.&#xD;
&#xD;
          -  Any clinically significant condition or abnormal findings at the Screening Visit that&#xD;
             would, in the opinion of the Investigator, preclude study participation or interfere&#xD;
             with the evaluation of the study medication.&#xD;
&#xD;
          -  Any skin disease or condition including eczema, psoriasis, melanoma, acne, contact&#xD;
             dermatitis, scarring, imperfections, lesions, tattoos, or discoloration that may&#xD;
             affect treatment application, application site assessments or absorption of the trial&#xD;
             drug.&#xD;
&#xD;
          -  History of treatment for, or evidence of, drug abuse within the past year.&#xD;
&#xD;
          -  Previous participation in a ZYN002 study (with the exception of patients who were&#xD;
             screen failures in Study ZYN2-CL-016 and did not enter Study ZYN2-CL-017).&#xD;
&#xD;
          -  Patient responds &quot;yes&quot; to Question 4 or 5 on the C-SSRS (Children) during Screening or&#xD;
             at any time on study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nancy Tich, PhD</last_name>
    <phone>973-727-4117</phone>
    <email>tichn@zynerba.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephen O'Quinn, PharmD</last_name>
    <phone>919-271-1339</phone>
    <email>oquinns@zynerba.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC Davis Health System, MIND Institute</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Randi Hagerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cynthia Fundora</last_name>
      <email>cxf157@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara Coffey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rare Disease Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han Phan, MD</last_name>
      <email>info@rarediseaseresearch.com</email>
    </contact>
    <investigator>
      <last_name>Han Phan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vantasia Joe</last_name>
      <email>Vantasia_V_Joe@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Berry-Kravis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kennedy Krieger Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine Eliades</last_name>
      <email>eliades@kennedykrieger.org</email>
    </contact>
    <investigator>
      <last_name>Dejan Budimirovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katherine Pawlowski</last_name>
      <email>katherine.pawlowski@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa Prock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Fragile X Clinic (Voyager Clinic)</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Desirae Rambeck</last_name>
      <email>drambeck@umphysicians.umn.edu</email>
    </contact>
    <investigator>
      <last_name>Amy Esler, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angelina Sharp</last_name>
      <email>asharp@umc.edu</email>
    </contact>
    <investigator>
      <last_name>Brad Ingram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Milen Velinov, MD</last_name>
      <email>mv662@rwjms.rutgers.edu</email>
    </contact>
    <contact_backup>
      <last_name>Felicia Balsamo</last_name>
      <email>fb313@rwjms.rutgers.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Milen Velinov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haiping Qiao</last_name>
      <email>hqiao@upa.chob.edu</email>
    </contact>
    <investigator>
      <last_name>Taosheng Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fragile X Spectrum Disorder Clinic at Icahn School of Medicine at Mount Sinai, Division of Medical Genetics</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>nicole.gonzalez@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Reymundo Lozano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Autism and Developing Brain</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miranda Zuniga-Kennedy</last_name>
      <email>miranda.zuniga-kennedy@nyspi.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Jeremy Veenstra-Vandervelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hannah Riehl</last_name>
      <email>Hannah.Riehl@cidd.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Jamie Capal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Danielle Chin</last_name>
      <email>Danielle.Chin@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Craig Erickson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central States Research</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Lisenbee</last_name>
      <phone>918-645-5400</phone>
      <email>christyl@centralstatesresearch.com</email>
    </contact>
    <investigator>
      <last_name>Sarah Land, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Patricia Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenwood Genetic Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah English</last_name>
      <email>senglish@ggc.org</email>
    </contact>
    <investigator>
      <last_name>Carrie Buchanan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Patricia Evans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Victoria Wilkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Children's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>sushma.sureshchandra@health.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <email>thayalini.shanmuganathan@health.nsw.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Natalie Silove, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lady Cilento Children's Hospital - South Brisbane</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Milburn</last_name>
      <email>emily.milburn@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Honey Heussler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Genetics Clinics Australia</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3161</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>travel@travelclinic.com.au</email>
    </contact>
    <investigator>
      <last_name>Jonathan Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellcome Trust HRB Clinical Research</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Louise Gallagher, MD</last_name>
    </contact>
    <investigator>
      <last_name>Louise Gallagher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Stanfield, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andrew Stanfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leicester Clinical Research</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julian Barwell, MD</last_name>
    </contact>
    <investigator>
      <last_name>Julian Barwell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andre Strydom</last_name>
    </contact>
    <investigator>
      <last_name>Andre Strydom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Ireland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Genetics and Inherited Disorders</keyword>
  <keyword>Other human genetics and inherited disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fragile X Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

